查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球前列腺增生市場-2022-2029
市場調查報告書
商品編碼
1140745

全球前列腺增生市場-2022-2029

Global Benign Prostate Hyperplasia (BPH) Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

增加老年人口是市場增長的驅動力

良性前列腺增生 (BPH) 越來越成為老年男性日益關注的健康問題。隨著老年男性人數的增加，這個問題的嚴重程度預計在未來幾年會翻一倍。世界老年人口正在顯著增加。近年來，美國的老年人口不斷增加。例如，到 2020 年，大約 16.9% 的美國人口將超過 65 歲，預計到 2050 年將達到 22%。此外，美國的出生率在過去 20 年一直在下降。在美國，加利福尼亞州和佛羅裡達州占主導地位。根據世界衛生組織 (WHO) 的估計，到 2030 年，六分之一的人將超過 60 歲。 60歲及以上人口比例將從2020年的10億增加到14億。到 2050 年，全球 60 歲及以上的人口將翻一番。從 2020 年到 2050 年，80 歲及以上的人口預計將增加兩倍，達到 4.26 億。大約一半的男性在 60 歲時發生組織病理學 BPH，90% 到 85 歲時發生。 BPH 的症狀影響全球 3000 萬男性和美國 1400 萬男性。

此外，對前列腺癌和其他泌尿系統疾病的認識不斷提高，以及全球良性前列腺增生 (BPH) 患者數量的增加，也推動了需求。

但是，與 BPH 藥物相關的副作用正在阻礙市場增長。良性前列腺增生的治療包括藥物治療和手術治療，兩者都有嚴重的副作用。ALPHA-受體阻滯劑、5-ARI（5-ALPHA還原□抑製劑）和其他類別的藥物廣泛用於治療 BPH。頭暈、體位性低血壓、逆行射精和鼻炎都是ALPHA受體阻滯劑的典型副作用。頭暈和直立性低血壓在老年人中很常見，並導致跌倒和骨折等嚴重問題。與藥物使用相關的並發症是預計在預測期內抑制全球市場增長的關鍵因素。

地理滲透率

北美將是預測期內的主要地區。

該研究按地區分析了全球市場的 BPH 市場，包括北美、歐洲、亞太地區、南美、中東和非洲。

北美將在 2021 年主導全球良性前列腺增生 (BPH) 市場。在北美，預計美國在預測期內將出現大幅增長。 BPH 和其他相關下尿路症狀的高患病率。過去十年的多項研究表明，美國大量 45 至 80 歲的男性患有下尿路症狀，其中大多數人出現 BPH 症狀，因此，良性前列腺增生 (BPH) 市場） 很大。此外，預計美國在預測期內的價值將出現顯著增長。預計對研發和先進產品開發的大量投資將推動區域市場的增長。

由於人口眾多，尤其是在印度和中國，預計亞太地區良性前列腺增生 (BPH) 市場將在預測期內快速增長。此外，預計不斷上漲的醫療成本和各種泌尿系統疾病患病率的激增將推動亞太地區良性前列腺增生（BPH）市場的增長。

競爭格局

由於大型醫療公司的存在，良性前列腺增生 (BPH) 市場是一個競爭激烈的市場。對全球市場增長做出貢獻的主要公司有 Endo International plc、KARL STORZ GMBH &CO.KG、Lumenis、Olympus Corporation、Urologix Inc、Boston Scientific Corporation、Coloplast A/S、Lisa Laser、Medifocus Inc、Neotract Inc 等。領先公司正在為良性前列腺增生 (BPH) 市場的全球增長採用新產品發布和擴張戰略。 2020 年 12 月，Endo International plc 以每股 88.50 美元的全現金交易收購了商業階段的生物製藥公司 BioSpecifics Technologies Corp.。通過此次收購，公司擴大了其 XIAFLEX 和 Qwo 產品的調整後 EBITDA 和盈利能力。這兩款產品是我們最耐用、最具差異化的產品，具有顯著的長期增長潛力。 2021 年 8 月，Stride Pharma 以 2400 萬美元收購了總部位於美國的 Endo International plc 的子公司。通過此次收購，該公司從 Endo International plc 收購了 20 種新產品。此次收購將使 Stride Pharma 在美國的產品組合翻一番，並可能每季度推出五到六種新產品。 2022 年 8 月，Teleflex 宣布與 Fundamental VR 合作，通過虛擬現實模擬改進培訓。通過此次合作，VR 培訓平台和 Teleflex 加速了公司 Urolift 2 系統的有效使用，該系統是一種良性前列腺增生 (BPH) 治療技術。

COVID-19 的影響。它對全球良性前列腺增生（BPH）市場產生了負面影響。

預計 COVID-19 流行病將對 BPH 治療行業產生重大影響。建議推遲良性病變的擇期手術，直到 COVID-19 對醫療保健系統造成壓力，醫院正在對服務進行大量投資，以應對 COVID-19 爆發的潛在增加。面對需求。因此，TURP、HoLEP、ThuLEP 和 PVP 等外科手術不得不推遲。

全球 BPH 市場報告提供對大約 61 個市場數據表、52 個圖表和 170 頁的訪問。

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按藥物類型劃分的市場細分
  • 手術市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 老年人口增加
      • 提高對前列腺癌和其他泌尿系統疾病的認識
    • 抑制因素
      • 抑制因素：良性前列腺增生藥物的副作用
    • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST 分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求
  • 專利趨勢

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按藥物類型

  • ALPHA 阻滯劑
  • 5-ALPHA還原□抑製劑

第 8 章外科手術

  • 防水布
  • TUMT
  • TUNA
  • 其他

第 9 章最終用戶

  • 醫院
  • 居家護理
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • Endo International plc
    • 公司概況
    • 藥物類型組合和描述
    • 主要亮點
    • 財務摘要
  • KARL STORZ GMBH & CO.KG.
  • Lumenis
  • Olympus Corporation
  • Urologix Inc.
  • Boston Scientific Corporation
  • Coloplast A/S
  • Lisa Laser
  • Medifocus Inc.
  • Neotract Inc.（LIST NOT EXHAUSTIVE）

第 13 章重要注意事項

第 14 章 DataM

簡介目錄
Product Code: DMPH3158

Market Overview

Benign Prostate Hyperplasia (BPH) Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 6 % during the forecast period (2022-2029).

BPH (benign prostatic hyperplasia) is a urological disease marked by the non-cancerous proliferation of prostate gland cells. The gland enlarges due to this disease, rubbing against the urethra and limiting urine flow. Ageing, hormonal imbalances, and irregular cell growth are also related to this disease. BPH is characterized by excessive urination, trouble starting urine, a poor urinary tract, and the inability to drain the urinary bladder. Men with mild to moderate BPH are currently treated with drugs. The growth in the male geriatric population is driving the global benign prostatic hyperplasia therapeutics industry.

Market Dynamics: The rise in geriatric population drives market growth

BPH (benign prostatic hyperplasia) is becoming more commonly recognized as a growing health concern among elderly men. The magnitude of the problem is predicted to multiply in the coming years as the number of elderly men increases. The global geriatric population is growing significantly. In the past few years, the aging population of the United States increasing. For instance, in 2020, about 16.9 percent of the American population was 65 years old or over, which is expected to reach 22 percent by 2050. In addition birth rate in the United States has been falling over the last 20 years. California and Florida are the dominant states in the United States. According to World Health Organization's estimated data, by 2030, 1 in 6 people will be aged 60 years or above. The share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double. The aging population above 80 or older is expected to triple between 2020 and 2050 to reach 426 million. By the age of 60, nearly half of men have histopathologic BPH, and by the age of 85, 90% of men have it. BPH signs affect 30 million men globally and 14 million men in the United States.

Other factors driving demand development include increased awareness of prostate cancer and other urological diseases and a rise in the number of patients with benign prostatic hyperplasia worldwide.

However, the side effects associated with BPH medications hamper the market growth. Although both medications and surgery can be used to treat BPH, both have serious side effects. Alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other drug groups are widely used to treat BPH. Dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis are all typical side effects of alpha-blockers. Dizziness and orthostatic hypotension are most frequent in the elderly, leading to severe problems such as falls and fractures. The complications associated with the use of drugs are a key factor expected to curtail the growth of the global market over the forecast period.

Market Segmentation: TURP segment is projected to be the dominant segment in the market during the forecast period.

The global benign prostate hyperplasia (BPH) is segmented based on surgery, which includes TURP, TUMT, TUNA and Others.

TURP held the dominant position in the global market during the forecast period owing to the surge in TURP surgery globally. Prostate transurethral resection is a urological technique used to treat benign prostatic hyperplasia (BPH). It includes visualizing the prostate through the urethra and cutting tissue with electrocautery or sharp dissection. As a result, the demand is expected to increase as TURP becomes more common. Moreover, the TURP is expected to project a considerable CAGR during the forecast period.

Benign prostate hyperplasia (BPH) is segmented based on end-user, which includes hospitals, home care and others.

The homecare segment held a significant market share in the forecast period. The majority of patients are given drugs instead of surgery. Patients should continue taking their medications for a few weeks after surgery. As a result, the market is driven by home treatment compared to hospital services. Moreover, the demand is expected to increase with a rising preference for home care settings. Therefore, home care is expected to project a considerable CAGR during the forecast period.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the Benign Prostate Hyperplasia (BPH) market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America held a dominant position in the global benign prostate hyperplasia (BPH) market in 2021. In North America, the U.S. is expected to represent considerable growth during the forecast period. High prevalence of BPH and other associated lower urinary tract symptoms. Several studies over the past decade have shown that a large number of men in the U.S. aged 45 to 80 suffer from lower urinary tract symptoms, with the bulk of them experiencing BPH symptoms, which results in a huge market for benign prostate hyperplasia (BPH). Moreover, the United States is expected to represent significant growth in terms of value during the forecast period. Significant investment in R&D and advanced product development is expected to propel regional market growth.

The benign prostate hyperplasia (BPH) market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the large population base, especially in India and China. Moreover, the rise in health care expenditure and the rapidly increasing prevalence of various urologic diseases are expected to augment the growth of the Asia Pacific Benign Prostate Hyperplasia (BPH) market.

Competitive Landscape:

The benign prostate hyperplasia (BPH) market is highly competitive, owing to the presence of big medical companies. The key players which are contributing to the growth of the global market include Endo International plc, KARL STORZ GMBH & CO.KG, Lumenis, Olympus Corporation., Urologix Inc., Boston Scientific Corporation, Coloplast A/S, Lisa Laser, Medifocus Inc, Neotract Inc, among others. The major players are adopting new product launches and expansion strategies for global growth in the benign prostate hyperplasia (BPH) market. In December 2020, Endo International plc acquired BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction. Through this acquisition, the company expanded its adjusted EBITDA and the profitability profile of both XIAFLEX and Qwo. These two products are the most durable and differentiated products with significant long-term growth potential. In August 2021, Strides Pharma acquired arms of Endo International plc (Endo) in the U.S. for $24 million. Through this acquisition, the company acquired 20 new commercial products from Endo International plc. Through this acquisition, Strides Pharma doubled its U.S. portfolio, potentially launching 5-6 new products each quarter. In August 2022, Teleflex announced a collaboration with Fundamental VR to improve training through virtual reality simulation. Through this collaboration Teleflex with a VR training platform to accelerate the effective use of the company's UroLift 2 system, a technology for treating benign prostatic hyperplasia (BPH).

COVID-19 Impact: Negative impact on the global benign prostate hyperplasia (BPH) market.

The COVID-19 epidemic is projected to have a major effect on the BPH care industry. Elective surgeries with benign pathology were advised to be deferred until the burden on the medical system from COVID-19 lessened, so hospitals will face a tremendous need for services to tackle a potential rise in COVID-19 incidents. Surgical operations such as TURP, HoLEP, ThuLEP, and PVP had to be delayed as a result.

The global benign prostate hyperplasia (BPH) market report would provide an access to approximately 61 market data tables, 52 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market Snippet by Surgery
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in Geriatric Population
      • 4.1.1.2. Increasing awareness of prostate cancer and other urological diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. Side-effects associated with BPH medications
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 7.3. Market Attractiveness Index, By Drug Type Segment
    • 7.3.1. Alpha Blocker*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. 5-Alpha Reductase Inhibitors

8. By Surgery

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery Segment
  • 8.3. Market Attractiveness Index, By Surgery Segment
    • 8.3.1. TURP*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. TUMT
    • 8.3.3. TUNA
    • 8.3.4. Others

9. By End User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
  • 9.3. Market Attractiveness Index, By End User Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Home Care
    • 9.3.3. Others

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Surgery
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Endo International plc*
    • 12.1.1. Company Overview
    • 12.1.2. Drug Type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. KARL STORZ GMBH & CO.KG.
  • 12.3. Lumenis
  • 12.4. Olympus Corporation
  • 12.5. Urologix Inc.
  • 12.6. Boston Scientific Corporation
  • 12.7. Coloplast A/S
  • 12.8. Lisa Laser
  • 12.9. Medifocus Inc.
  • 12.10. Neotract Inc. (LIST NOT EXHAUSTIVE)

13. Premium Insights

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us